CN119546752A - 炎性病况的治疗 - Google Patents

炎性病况的治疗 Download PDF

Info

Publication number
CN119546752A
CN119546752A CN202380034277.3A CN202380034277A CN119546752A CN 119546752 A CN119546752 A CN 119546752A CN 202380034277 A CN202380034277 A CN 202380034277A CN 119546752 A CN119546752 A CN 119546752A
Authority
CN
China
Prior art keywords
virus
vlp
protein
galectin
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380034277.3A
Other languages
English (en)
Chinese (zh)
Inventor
上野隆司
赤田涉
后藤和也
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyn K Biotech Co
Kyoto University NUC
Original Assignee
Cyn K Biotech Co
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyn K Biotech Co, Kyoto University NUC filed Critical Cyn K Biotech Co
Publication of CN119546752A publication Critical patent/CN119546752A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202380034277.3A 2022-04-18 2023-04-14 炎性病况的治疗 Pending CN119546752A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263332037P 2022-04-18 2022-04-18
US63/332037 2022-04-18
PCT/JP2023/015132 WO2023204148A1 (en) 2022-04-18 2023-04-14 Treatment of inflammatory conditions

Publications (1)

Publication Number Publication Date
CN119546752A true CN119546752A (zh) 2025-02-28

Family

ID=88308716

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380034277.3A Pending CN119546752A (zh) 2022-04-18 2023-04-14 炎性病况的治疗

Country Status (5)

Country Link
US (1) US20230330209A1 (https=)
EP (1) EP4511479A1 (https=)
JP (1) JP2025513920A (https=)
CN (1) CN119546752A (https=)
WO (1) WO2023204148A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118812696A (zh) * 2024-08-21 2024-10-22 南通大学附属医院 Galectin-3抗原表位肽、抗原、抗体及化学发光试剂盒

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969986B2 (en) * 2014-08-08 2018-05-15 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
EP4326858A4 (en) * 2021-04-23 2025-03-12 VLP Therapeutics, Inc. GALECTIN-TARGETED IMMUNOTHERAPY

Also Published As

Publication number Publication date
US20230330209A1 (en) 2023-10-19
WO2023204148A1 (en) 2023-10-26
EP4511479A1 (en) 2025-02-26
JP2025513920A (ja) 2025-04-30

Similar Documents

Publication Publication Date Title
JP7701080B2 (ja) アルファウイルスレプリコン粒子
KR20230049084A (ko) Sars-cov-2 및 인플루엔자 조합 백신
US9339535B2 (en) Vaccines and immunopotentiating compositions and methods for making and using them
KR20220010478A (ko) 기도 감염의 치료 또는 예방용 서브유닛 백신
BR112015030229B1 (pt) Partícula semelhante a vírus compreendendo um polipeptídeo e um antígeno da malária, vetor, composições farmacêutica e de vacina, bem como molécula de ácido nucleico isolado
CA3075990A1 (en) Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (rsv) infections
US20130052226A1 (en) Compositions and methods for preventing or treating a human parvovirus infection
WO2023204148A1 (en) Treatment of inflammatory conditions
US20220347261A1 (en) Galectin-targeting immunotherapy
JP6675185B2 (ja) 免疫誘導剤およびその製造方法
ES2282156T3 (es) Vacuna de acido nucleico.
WO2025084276A1 (ja) 肥満の処置
WO2024143497A1 (ja) Ｃｄ１５３を標的とする医薬組成物
RU2811991C2 (ru) Субъединичная вакцина для лечения или предотвращения инфекции дыхательных путей
CN106456742A (zh) 用于治疗(包括预防)细小病毒感染及相关疾病的组合物和方法
EP3527223A1 (en) Mutated parvovirus structural protein
OA20123A (en) Alphavirus replicon particle.
JPWO2005090576A1 (ja) 百日咳感染症予防用ｄｎａ構築物
BR112012032922A2 (pt) construções de proteína homodimérica

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination